Notably, the United States Food and Drug Administration (FDA) has approved using PD-1/PD-L1 inhibitors pembrolizumab and nivolumab for patients with dMMR-MSI-H colorectal cancer [73]. This evidence concerns the gene PDCD1 and colorectal cancer.